New medications for adults with type 2 diabetes are to be produced at a new high-capacity manufacturing plant in the UK.
Aesican, the UK-based contract manufacturing organisation (CMO), opened the doors to its new £30 million facility in Queenborough, Kent, yesterday which will have the sole purpose of manufacturing solid dose (oral) drug treatments for type 2 diabetes.
The drug developer/manufacturer confirmed that work at the new 10,000 square-metre site will begin in November, starting with the production of an unnamed drug, and that products made at the plant will be distributed to markets worldwide.
The plant will be staffed by 55 Aesica technicians, all of whom will be recruited from the local area and trained on site.
Aesica Pharmaceuticals chief executive Dr Robert Hardy said: “The new investment and opening of the high-capacity manufacturing facility marks another key milestone for our company and a further step towards achieving our vision to be the world’s number one supplier to the pharmaceutical industry.
“The formulation of the solid dose product for the treatment of Type 2 diabetes is a perfect example of the type of high-quality and high-healthcare demand drugs that we manufacture for supply to the international market place.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…